Noxopharm’s Sofra™ technology has received promising external validation from BioRay Pharmaceutical, confirming its targeted anti-inflammatory potential and broad applicability in autoimmune disease therapies.
- BioRay Pharmaceutical confirms targeted anti-inflammatory activity of Sofra™ oligonucleotides
- Successful conjugation of Noxopharm’s oligos enhances BioRay’s antibody drug performance
- Material Transfer Agreement with BioRay marks a key international collaboration
- Results validate the robustness and versatility of the Sofra™ technology platform
- Further joint studies planned to explore Sofra’s potential across autoimmune treatments
A New Chapter for Sofra™ Technology
Australian biotech company Noxopharm Limited (ASX, NOX) has announced encouraging results from its collaboration with BioRay Pharmaceutical, a major player in China’s biopharmaceutical sector. BioRay’s independent testing of Noxopharm’s Sofra™ platform oligonucleotides has demonstrated significant anti-inflammatory activity, reinforcing the promise of this innovative technology.
BioRay, with over 1,800 employees and a global footprint spanning China and the US, is well-regarded for its work in immune-mediated diseases. The company’s decision to explore Noxopharm’s oligonucleotides under a Material Transfer Agreement (MTA) reflects growing international interest in Sofra’s potential applications.
Enhancing Antibody-Drug Conjugates
The collaboration focused on the use of Sofra oligonucleotides as targeted drugs within antibody-drug conjugates (ADCs), a sophisticated approach where therapeutic agents are linked to antibodies for precise delivery. BioRay’s research confirmed that conjugation to a specific Noxopharm oligo was achievable and that this conjugation significantly improved the efficacy of BioRay’s own antibodies designed to combat autoimmune diseases.
Specifically, the conjugated drug combination reduced a key biological marker of inflammation more effectively than the antibody alone, suggesting a powerful synergy. This external validation not only supports the robustness of Noxopharm’s data but also highlights the broad versatility of the Sofra platform across different therapeutic areas.
Strategic Implications and Future Directions
Dr Gang Chen, BioRay’s Head of R&D, expressed enthusiasm about the collaboration, emphasizing the strategic value and promising efficacy of the Sofra assets. Meanwhile, Noxopharm’s CEO, Dr Gisela Mautner, underscored the importance of such partnerships in advancing the company’s innovative drug development pipeline.
This MTA with BioRay is one among several international collaborations, positioning Noxopharm to leverage global expertise and accelerate the commercial potential of its Sofra technology. With further studies underway, the coming months will be critical in defining the scope and impact of these joint efforts.
As Noxopharm continues to explore Sofra’s applications in inflammation, autoimmunity, and oncology, the validation from a respected overseas partner marks a significant milestone in the company’s journey from clinical-stage research to potential market success.
Bottom Line?
Noxopharm’s Sofra platform is gaining international traction, setting the stage for broader development and potential commercial breakthroughs.
Questions in the middle?
- What are the timelines and milestones for BioRay’s ongoing studies with Sofra assets?
- Could this collaboration lead to a formal commercial partnership or licensing agreement?
- How will Sofra’s validation impact Noxopharm’s valuation and investor confidence?